血浆高迁移率族蛋白 B1 水平与缺血性脑卒中临床结局的关系。
Relationship between plasma high-mobility group box-1 levels and clinical outcomes of ischemic stroke.
机构信息
Department of Neurology, The First Hospital of Jia Xing, Jiaxing, 314001, PR China.
出版信息
J Crit Care. 2013 Oct;28(5):792-7. doi: 10.1016/j.jcrc.2012.10.003. Epub 2012 Nov 6.
PURPOSE
High-mobility group box-1 (HMGB1) is regarded as a central mediator of inflammation and involved in many inflammatory diseases. This study aimed to investigate impact of plasma HMGB1 level on 1-year clinical outcomes of ischemic stroke.
METHODS
Plasma HMGB1 levels of 338 patients were quantified by enzyme-linked immunosorbent assay. The end points were mortality and unfavorable outcome (modified Rankin Scale score>2) after 1 year.
RESULTS
Plasma HMGB1 level emerged as an independent predictor of 1-year clinical outcomes. Its prognostic value was similar to National Institutes of Health Stroke Scale score's. It improved prognostic value of National Institutes of Health Stroke Scale score.
CONCLUSION
Plasma HMGB1 level represents a novel biomarker for predicting 1-year clinical outcomes of ischemic stroke.
目的
高迁移率族蛋白 B1（HMGB1）被认为是炎症的中心介质，参与许多炎症性疾病。本研究旨在探讨血浆 HMGB1 水平对缺血性脑卒中患者 1 年临床结局的影响。
方法
采用酶联免疫吸附试验定量检测 338 例患者的血浆 HMGB1 水平。终点为 1 年后的死亡率和不良结局（改良 Rankin 量表评分>2）。
结果
血浆 HMGB1 水平是 1 年临床结局的独立预测因子。其预后价值与国立卫生研究院卒中量表评分相似。它提高了国立卫生研究院卒中量表评分的预后价值。
结论
血浆 HMGB1 水平是预测缺血性脑卒中患者 1 年临床结局的新型生物标志物。
Zotero 插件